Compare TRUP & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | IMCR |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2014 | 2021 |
| Metric | TRUP | IMCR |
|---|---|---|
| Price | $34.13 | $37.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $56.33 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 504.5K | 323.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,399,759,000.00 | $379,590,000.00 |
| Revenue This Year | $13.17 | $30.11 |
| Revenue Next Year | $7.90 | $8.89 |
| P/E Ratio | $97.56 | ★ N/A |
| Revenue Growth | 12.50 | ★ 28.11 |
| 52 Week Low | $31.00 | $23.15 |
| 52 Week High | $57.89 | $40.53 |
| Indicator | TRUP | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 28.71 | 54.88 |
| Support Level | $34.74 | $38.23 |
| Resistance Level | $36.62 | $40.53 |
| Average True Range (ATR) | 1.37 | 1.49 |
| MACD | -0.15 | 0.04 |
| Stochastic Oscillator | 9.13 | 49.44 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.